XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Common Stock Class A
Common Stock
Common Stock Class B
Additional Paid- in Capital
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Statutory Surplus Reserve
Accumulated Other Comprehensive Income (Loss)
Non-controlling Interests
Beginning balance (in shares) at Dec. 31, 2021 [1]     53,608,929 5,087,814            
Beginning balance at Dec. 31, 2021 $ 811,665   $ 5 $ 1 $ 595,045 $ 63,732   $ 8,312 $ 9,109 $ 135,461
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) 36,381         27,454       8,927
Foreign currency translation adjustment (80,334)               (67,029) (13,305)
Exercise of stock options (in shares) [1]     763,584              
Exercise of stock options 1,150       1,150          
Stock-based compensation 5,236       5,236          
Conversion of class B common stock to Class A common stock (in shares) [1]     1,002 (1,002)            
Conversion of Class B common stock to Class A common stock 1,002                  
Ending balance (in shares) at Sep. 30, 2022 [1]     54,373,515 5,086,812            
Ending balance at Sep. 30, 2022 774,098   $ 5 $ 1 601,431 91,186   8,312 (57,920) 131,083
Beginning balance (in shares) at Jun. 30, 2022     54,141,805 5,086,812            
Beginning balance at Jun. 30, 2022 787,145   $ 5 $ 1 599,138 70,182   8,312 (22,633) 132,140
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) 27,076         21,004       6,072
Foreign currency translation adjustment (42,416)               (35,287) (7,129)
Exercise of stock options (in shares)     231,710              
Exercise of stock options 400       400          
Stock-based compensation 1,893       1,893          
Ending balance (in shares) at Sep. 30, 2022 [1]     54,373,515 5,086,812            
Ending balance at Sep. 30, 2022 774,098   $ 5 $ 1 601,431 91,186   8,312 (57,920) 131,083
Beginning balance (in shares) at Dec. 31, 2022     54,655,286 5,021,811            
Beginning balance at Dec. 31, 2022 812,171                  
Beginning balance at Dec. 31, 2022 812,171 $ (1,769) $ 5 $ 1 604,089 94,426 $ (1,769) 16,881 (40,546) 137,315
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) 73,554         59,649       13,905
Foreign currency translation adjustment (21,831)               (19,808) (2,023)
Exercise of stock options (in shares)     919,448              
Exercise of stock options 5,290   $ 1   1,455         3,834
ACM Shanghai dividend (3,951)         0       (3,951)
Stock-based compensation 14,666       14,666          
Conversion of Class B common stock to Class A common stock 0                  
Ending balance (in shares) at Sep. 30, 2023     55,574,734 5,021,811            
Ending balance at Sep. 30, 2023 878,130                  
Ending balance at Sep. 30, 2023 878,130   $ 6 $ 1 620,210 152,306   16,881 (60,354) 149,080
Beginning balance (in shares) at Jun. 30, 2023     54,951,490 5,021,811            
Beginning balance at Jun. 30, 2023 831,775   $ 5 $ 1 608,865 126,627   16,881 (61,916) 141,312
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net income (loss) 30,994         25,679       5,315
Foreign currency translation adjustment 4,015               1,562 2,453
Exercise of stock options (in shares)     623,244              
Exercise of stock options 765   $ 1   764          
Stock-based compensation 10,581       10,581          
Ending balance (in shares) at Sep. 30, 2023     55,574,734 5,021,811            
Ending balance at Sep. 30, 2023 878,130                  
Ending balance at Sep. 30, 2023 $ 878,130   $ 6 $ 1 $ 620,210 $ 152,306   $ 16,881 $ (60,354) $ 149,080
[1] (1) Share numbers as of December 31, 2021 have been adjusted to reflect the three-for-one stock split effected in the form of a stock dividend in March 2022. See Note 2 for details.